

For personal use only

Interim Report:  
Half - Year ended  
31 December 2022

# Radiopharm Theranostics Limited

## Appendix 4D

### Half-year ended 31 December 2022

**Name of entity:** Radiopharm Theranostics Limited  
**ABN:** 57 647 877 889  
**Half-year ended:** 31 December 2022

#### Results for announcement to the market

					\$
Revenue for ordinary activities	-	-%	to	-	
Loss from ordinary activities after tax attributable to members	Up	27.8%	to	12,552,283	
Net loss for the period attributable to members	Up	27.8%	to	12,552,283	

#### Net tangible assets per security

	31 December 2022 Cents	31 December 2021 Cents
Net tangible asset backing (per security)	2.03	6.19

#### Explanation of results

An explanation of the key financial elements contributing to the revenue and result above can be found in the review of operations included within the directors' report.

#### Distributions

No dividends have been paid or declared by the group for the current financial period. No dividends were paid for the previous financial period.

#### Changes in controlled entities

On 9 July 2022, Radiopharm Theranostics (USA), Inc. and The University of Texas MD Anderson Cancer Center formed Radiopharm Ventures, LLC, a joint venture to develop novel radiopharmaceutical therapeutic products for cancer. The joint venture will focus initially on developing products based on MD Anderson intellectual property. Radiopharm Ventures, LLC is a limited liability company jointly owned by Radiopharm Theranostics (USA) Inc. (a wholly owned subsidiary of Radiopharm) (51%) and MD Anderson (49%). The University of Texas MD Anderson Cancer Center has granted a license to Radiopharm Ventures for certain patent and technology rights for development and commercialisation.

There have been no other changes in controlled entities during the half-year ended 31 December 2022.

(continued)

**Other information required by Listing Rule 4.2A**

a. Details of individual and total dividends or distributions and dividend or distribution payments:	N/A
b. Details of any dividend or distribution reinvestment plans:	N/A
c. Details of associates and joint venture entities:	N/A
d. Other information	N/A

**Interim review**

The financial statement have been reviewed by the group's independent auditor who has issued an unmodified opinion with a material uncertainty in relation to going concern.

# Review of Operations & Activities

*Half-year ended: 31 December 2022*

Radiopharm Theranostics Limited is developing a world-class platform of radiopharmaceutical and nuclear medicine products for both diagnostic and therapeutic uses.

## Financial Review

The group reported a loss for the half-year ended 31 December 2022 of \$12,552,283 (31 December 2021: \$17,390,804). The loss is due to expenditure relating to operating activities in the group and the clinical trial and research activities that have been undertaken.

The group's net assets have increased to \$63,124,898 (30 June 2022: 62,962,719). As at 31 December 2022, the group had cash reserves of \$24,245,939 (30 June 2022: 26,979,105).

## Operating Review

### Radiopharm activities

During the period, Radiopharm produced positive Pivalate Phase 2a data in patients with brain metastases. The data demonstrated that F-18 Pivalate PET showed high uptake regardless of the origin of the primary tumour and can also be used to monitor cerebral metastases. In October 2022, this data was presented at the 34th EORTC/AACR/NCI symposium in Barcelona.

In December 2022, the Company received US Food and Drug Administration (FDA) Investigational New Drug Application (IND) approval for its  $\alpha V\beta 6$  Integrin (RAD301) technology. The approval allows the Company to begin a Phase 1 imaging trial in patients with pancreatic cancer, targeting commencement at the end of Q1 CY23 with an estimated close by Q3 CY23.

Also in December 2022, positive imaging data was published regarding the HER2 nanobody (RAD201) in the prestigious European Journal of Nuclear Medicine & Molecular Imaging. The publication highlighted that RAD201 is a 'promising non-invasive tool for discriminating HER2 status in metastatic (breast) cancer, regardless of ongoing HER2-targeted antibody treatment'. This is made possible due to RAD201's ability to bind to a different part of the HER2 receptor.

The publication indicated that RAD201 has a favourable biodistribution and showed high accumulation in all active HER2 positive tumour sites. It demonstrated a high target-to-background ratio, favourable tumour targeting and rapid blood clearance. The publication also supports previous data regarding the safety profile for use of RAD201 in humans.

The US Food and Drug Administration (FDA) granted Orphan Drug Designation for its DUNP19 technology for the treatment of osteosarcoma, a rare bone cancer that primarily affects children, adolescents and young adults. This designation is only granted for a drug or biologic product with the potential to diagnose, prevent or treat rare diseases and conditions. Currently surgery and chemotherapy are the only treatments available for this condition.

The FDA subsequently also granted Rare Paediatric Disease (RPD) designation for the Company's DUNP technology. This program is aimed at advancing the development of drugs with the potential to treat serious, rare paediatric diseases. The designation allows companies to receive a priority review

voucher (PRV) from the FDA when a marketing authorization is granted. This can be used to expedite approval or can be sold/transferred to other companies for use in the same manner.

### **RAD locks in key supply agreements**

This half year also saw Radiopharm form several key partnerships and agreements. Radiopharm and The University of Texas MD Anderson Cancer Centre announced the launch of Radiopharm Ventures, LLC, a joint venture company created to develop novel radiopharmaceutical therapeutic products for cancer. The initial focus of the venture will be on developing at least four therapeutic products based on MD Anderson intellectual products. The first potential therapeutic candidate is a humanised immunoglobulin G (IgG) antibody against the tumour-specific antigen B7-H3, which is highly expressed in several common tumours, but not in healthy cells.

Radiopharm also entered into a collaboration agreement with Lantheus for the mutually beneficial development of NM-01, a nanobody made using genetically engineered camelid derived single domain antibodies that can be labelled with radioisotopes for the potential diagnosis and treatment of multiple tumour types. Radiopharm also acquired the imaging rights of NM-01 from NanoMab for the strategic Chinese market and worldwide IP rights for any therapeutic use.

The Company also announced that it had extended its agreement with GenesisCare to support a second Radiopharm clinical trial. The trial will use Radiopharm's PSA targeting antibody to start a therapeutic Phase 1 in prostate cancer, the innovative approach and novel mode of action compared with other treatments currently under development make Radiopharm's technology highly prospective.

Radiopharm successfully formed three supply agreements for isotopes for production and commercialization of radiopharmaceuticals. The first was with SHINE Technologies which will supply Radiopharm with isotope non-carrier-added lutetium-177 (Lu-177). The isotope will be used in Radiopharm's clinical pipeline development of diagnostic and therapeutic radiopharmaceutical products. Lu-177 is an important isotope utilised in multiple programs across the Company's portfolio.

The second was with NorthStar Medical Radioisotopes, LLC for the supply for Actinium-225, key to the development of several radiopharmaceutical products within Radiopharm's broad portfolio of technologies, with this being the second supply agreement the Company has secured for Actinium-225. It will be utilised in drug trials involving targeted alpha therapy in multiple disease areas.

The last agreement was with Australia's Nuclear Science and Technology Organisation (ANSTO) to supply it with isotope non-carrier-added lutetium-177 (Lu-177) for Radiopharm's trials in Australia. The isotope will be used by in combination with Radiopharm's propriety nanobody in a Phase I therapeutic dose escalation trial in patients with non-small cell lung cancer. The trial is planned to start in Q2 2023 in collaboration with GenesisCare and ANSTO.

### **Funding Activities**

On 19 October 2022, Radiopharm announced a \$10m (before costs) Entitlement Offer comprising a \$5.5m institutional component and a \$4.5m retail component (with the latter subsequently confirmed to be fully underwritten by Bell Potter Securities Limited (Bell Potter)).

On 20 October 2022, Radiopharm confirmed the successful completion of the \$5.5m institutional component. Subsequently, on 22 November 2022, the retail component of the offer was successfully completed, raising \$1.2 million from retail investors, with the balance being subscribed for by Bell Potter. The capital raising provides the Company with runway until at least the end of 2023, including for the three new platform technologies acquired since the IPO.

For and on behalf of the company,

Riccardo Canevari  
Chief Executive Officer and Managing Director

# Radiopharm Theranostics Limited

ABN 57 647 877 889

## ***Interim report - 31 December 2022***

### **Contents**

Directors' report	Page 5
Interim financial report	
Consolidated statement of profit or loss and other comprehensive income	8
Consolidated statement of financial position	9
Consolidated statement of changes in equity	10
Consolidated statement of cash flows	12
Notes to the consolidated financial statements	13
Directors' declaration	36
Independent auditor's report to the members	37

## **Directors**

The following persons held office as directors of Radiopharm Theranostics Limited during the financial period and up to the date of this report:

Mr Paul Hopper  
Mr Riccardo Canevari  
Dr Michael Baker  
Mr Ian Turner  
Ms Hester Larkin  
Dr Leila Alland

## **Review of operations and activities**

Information on the financials and operations of the group and its business strategies and prospects is set out in the review of operations and activities on pages 1 to 3 of this interim financial report.

## **Significant changes in the state of affairs**

On 9 July 2022, Radiopharm Theranostics (USA) Inc. and The University of Texas MD Anderson Cancer Center formed Radiopharm Ventures, LLC, a joint venture to develop novel radiopharmaceutical therapeutic products for cancer. The joint venture will focus initially on developing products based on MD Anderson intellectual property. Radiopharm Ventures, LLC is a limited liability company jointly owned by Radiopharm Theranostics (USA) Inc. (a wholly owned subsidiary of Radiopharm) (51%) and MD Anderson (49%). The University of Texas MD Anderson Cancer Center has granted a license to Radiopharm Ventures for certain patent and technology rights for development and commercialisation.

On 25 October 2022 Radiopharm Theranostics Limited participated in an institutional entitlement offer on the Australian Stock Exchange and in the process raised \$5.8 million through the issue of 41,028,222 shares at \$0.14. Additionally, 32,073,235 shares were issued at \$0.14 via a rights issue raising an additional \$4.5 million.

In the opinion of the directors there were no other significant changes in the state of affairs of the group that occurred during the period.

## **Events since the end of the financial period**

On 14 February 2023, Radiopharm Theranostics Limited announced the initiation of the process to obtain a secondary listing on the Nasdaq Capital Market. The group has filed a registration statement on Form 20-F with the US Securities and Exchange Commission (SEC) and a listing application with Nasdaq.

No other matter or circumstance has occurred subsequent to period end that has significantly affected, or may significantly affect, the operations of the group, the results of those operations or the state of affairs of the group or economic entity in subsequent financial periods.

## **Auditor's independence declaration**

A copy of the auditor's independence declaration as required under section 307C of the *Corporations Act 2001* is set out on page 7.

## **Rounding of amounts**

The group is of a kind referred to in ASIC Legislative Instrument 2016/191, relating to the 'rounding off' of amounts in the directors' report and financial report. Amounts in the directors' report and financial report have been rounded off to the nearest dollar in accordance with the instrument.



This report is made in accordance with a resolution of directors.



Mr Paul Hopper  
Executive Chairman

Sydney  
28 February 2023

---

**Grant Thornton Audit Pty Ltd**


Level 22 Tower 5  
Collins Square  
727 Collins Street  
Melbourne VIC 3008  
GPO Box 4736  
Melbourne VIC 3001  
T +61 3 8320 2222

## Auditor's Independence Declaration

### To the Directors of Radiopharm Theranostics Limited

In accordance with the requirements of section 307C of the *Corporations Act 2001*, as lead auditor for the review of Radiopharm Theranostics Limited for the half-year ended 31 December 2022, I declare that, to the best of my knowledge and belief, there have been:

- a no contraventions of the auditor independence requirements of the *Corporations Act 2001* in relation to the review; and
- b no contraventions of any applicable code of professional conduct in relation to the review.



Grant Thornton Audit Pty Ltd  
Chartered Accountants



M A Cunningham  
Partner – Audit & Assurance  
Melbourne, 28 February 2023

[www.grantthornton.com.au](http://www.grantthornton.com.au)  
ACN-130 913 594

---

Grant Thornton Audit Pty Ltd ACN 130 913 594 a subsidiary or related entity of Grant Thornton Australia Limited ABN 41 127 556 389 ACN 127 556 389. 'Grant Thornton' refers to the brand under which the Grant Thornton member firms provide assurance, tax and advisory services to their clients and/or refers to one or more member firms, as the context requires. Grant Thornton Australia Limited is a member firm of Grant Thornton International Ltd (GTIL). GTIL and the member firms are not a worldwide partnership. GTIL and each member firm is a separate legal entity. Services are delivered by the member firms. GTIL does not provide services to clients. GTIL and its member firms are not agents of, and do not obligate one another and are not liable for one another's acts or omissions. In the Australian context only, the use of the term 'Grant Thornton' may refer to Grant Thornton Australia Limited ABN 41 127 556 389 ACN 127 556 389 and its Australian subsidiaries and related entities. Liability limited by a scheme approved under Professional Standards Legislation.

**Radiopharm Theranostics Limited**  
**Consolidated statement of profit or loss and other comprehensive income**  
**For the half-year ended 31 December 2022**

	Notes	31 December 2022 \$	31 December 2021 \$
Revenue from contracts with customers		292,359	-
Other income	2(a)	3,969,499	24
Other losses		16,002	(600,441)
General and administrative expenses		(5,398,606)	(3,293,983)
Research and development		(9,436,143)	(2,737,396)
Share-based payments		(1,455,088)	(2,240,688)
<b>Operating loss</b>		<b>(12,011,977)</b>	<b>(8,872,484)</b>
Finance expenses		(499,262)	(8,518,320)
<b>Loss before income tax</b>		<b>(12,511,239)</b>	<b>(17,390,804)</b>
Income tax expense		(41,044)	-
<b>Loss for the period</b>		<b>(12,552,283)</b>	<b>(17,390,804)</b>
<b>Other comprehensive loss</b>			
<i>Items that may be reclassified to profit or loss:</i>			
Foreign currency translation	5(b)	(911)	(12,512)
<b>Total comprehensive loss for the period</b>		<b>(12,553,194)</b>	<b>(17,403,316)</b>
Total comprehensive income for the period is attributable to:			
Owners of Radiopharm Theranostics Limited		(12,480,413)	(17,403,316)
Non-controlling interests	7(b)	(72,781)	-
		<b>(12,553,194)</b>	<b>(17,403,316)</b>
		<b>Cents</b>	<b>Cents</b>
<b>Loss per share for loss attributable to the ordinary equity holders of the group:</b>			
Basic/diluted loss per share	13	<b>(4.54)</b>	<b>(16.00)</b>

The above Consolidated statement of profit or loss and other comprehensive income should be read in conjunction with the accompanying notes.

**Radiopharm Theranostics Limited**  
**Consolidated statement of financial position**  
**As at 31 December 2022**

	31 December 2022	30 June 2022
Notes	\$	\$
<b>ASSETS</b>		
<b>Current assets</b>		
Cash and cash equivalents	24,245,939	26,979,105
Trade and other receivables	3(a) 4,078,533	56,482
Other current assets	184,524	228,818
<b>Total current assets</b>	<b>28,508,996</b>	<b>27,264,405</b>
<b>Non-current assets</b>		
Property, plant and equipment	72,648	1,578
Intangible assets	4(a) 56,447,112	56,075,308
Other financial assets	40,000	40,000
<b>Total non-current assets</b>	<b>56,559,760</b>	<b>56,116,886</b>
<b>Total assets</b>	<b>85,068,756</b>	<b>83,381,291</b>
<b>LIABILITIES</b>		
<b>Current liabilities</b>		
Trade and other payables	3(b) 1,918,307	2,153,318
Employee benefit obligations	175,038	93,141
Other financial liabilities	3(c) 11,790,804	5,632,168
<b>Total current liabilities</b>	<b>13,884,149</b>	<b>7,878,627</b>
<b>Non-current liabilities</b>		
Trade and other payables	3(b) 144,792	152,447
Other financial liabilities	3(c) 7,914,917	12,387,498
<b>Total non-current liabilities</b>	<b>8,059,709</b>	<b>12,539,945</b>
<b>Total liabilities</b>	<b>21,943,858</b>	<b>20,418,572</b>
<b>Net assets</b>	<b>63,124,898</b>	<b>62,962,719</b>
<b>EQUITY</b>		
Share capital	5(a) 95,698,275	86,758,783
Other reserves	5(b) 9,555,691	7,109,134
Accumulated losses	(43,384,700)	(30,905,198)
Non-controlling interests	1,255,632	-
<b>Total equity</b>	<b>63,124,898</b>	<b>62,962,719</b>

*The above Consolidated statement of financial position should be read in conjunction with the accompanying notes.*

**Radiopharm Theranostics Limited**  
**Consolidated statement of changes in equity**  
**For the half-year ended 31 December 2022**

	Attributable to owners of Radiopharm Theranostics Limited			Non- controlling interests	Total equity
	Share capital	Other reserves	Accumulated losses		
Notes	\$	\$	\$	\$	\$
<b>Balance at 1 July 2021</b>	1,000	359,487	(485,190)	-	(124,703)
Loss for the period	-	-	(17,390,804)	-	(17,390,804)
Other comprehensive loss	-	(12,512)	-	-	(12,512)
<b>Total comprehensive loss for the period</b>	-	(12,512)	(17,390,804)	-	(17,403,316)
<b>Transactions with owners in their capacity as owners:</b>					
Contributions of equity, net of transaction costs and tax	43,940,340	-	-	-	43,940,340
Conversion of convertible notes	26,666,667	-	-	-	26,666,667
Issue of shares as part of license acquisitions	15,333,333	-	-	-	15,333,333
Shares to be issued	-	103,363	-	-	103,363
Equity-settled payments	-	162,939	-	-	162,939
Issue of options	-	4,741,852	-	-	4,741,852
	85,940,340	5,008,154	-	-	90,948,494
<b>Balance at 31 December 2021</b>	<b>85,941,340</b>	<b>5,355,129</b>	<b>(17,875,994)</b>	<b>-</b>	<b>73,420,475</b>

The above Consolidated statement of changes in equity should be read in conjunction with the accompanying notes.

**Radiopharm Theranostics Limited**  
**Consolidated statement of changes in equity**  
**For the half-year ended 31 December 2022**  
(continued)

	Notes	Share capital \$	Other reserves \$	Accumulated losses \$	Non- controlling interests \$	Total equity \$
<b>Balance at 1 July 2022</b>		86,758,783	7,109,134	(30,905,198)	-	62,962,719
Loss for the period		-	-	(12,479,502)	(72,781)	(12,552,283)
Other comprehensive loss		-	(911)	-	-	(911)
<b>Total comprehensive loss for the period</b>		<b>86,758,783</b>	<b>7,108,223</b>	<b>(43,384,700)</b>	<b>(72,781)</b>	<b>50,409,525</b>
<b>Transactions with owners in their capacity as owners:</b>						
Non-controlling interest investment in Radiopharm Ventures, LLC		-	-	-	1,328,413	1,328,413
Contributions of equity, net of transaction costs and tax	5(a)	8,742,942	-	-	-	8,742,942
Issue of options	5(b)	-	2,350,786	-	-	2,350,786
Options forfeited		-	(133,297)	-	-	(133,297)
Equity-settled payments	5(b)	196,550	229,979	-	-	426,529
		<u>8,939,492</u>	<u>2,447,468</u>	<u>-</u>	<u>1,328,413</u>	<u>12,715,373</u>
<b>Balance at 31 December 2022</b>		<b>95,698,275</b>	<b>9,555,691</b>	<b>(43,384,700)</b>	<b>1,255,632</b>	<b>63,124,898</b>

The above Consolidated statement of changes in equity should be read in conjunction with the accompanying notes.

**Radiopharm Theranostics Limited**  
**Consolidated statement of cash flows**  
**For the half-year ended 31 December 2022**

	31 December 2022	31 December 2021
Notes	\$	\$
<b>Cash flows from operating activities</b>		
Receipts from customers (inclusive of GST)	292,352	-
Payments to suppliers and employees (inclusive of GST)	(12,382,543)	(4,818,313)
Receipts collected on behalf of third parties	1,194,681	-
Payments to third parties with respect to receipts collected on their behalf	(1,194,681)	-
Interest received	53,526	-
<b>Net cash outflow from operating activities</b>	<b>(12,036,665)</b>	<b>(4,818,313)</b>
<b>Cash flows from investing activities</b>		
Payments for intellectual property	-	(27,780,357)
Payments for property, plant and equipment	(73,306)	(2,749)
Payments for financial assets at amortised cost	-	(40,000)
<b>Net cash outflow from investing activities</b>	<b>(73,306)</b>	<b>(27,823,106)</b>
<b>Cash flows from financing activities</b>		
Proceeds from issues of shares and other equity securities	10,073,286	50,000,000
Share issue transaction costs	(836,764)	(3,538,194)
Proceeds from issue of convertible notes	-	18,758,342
Proceeds from borrowings	-	10,000
Repayment of borrowings	-	(69,000)
<b>Net cash inflow from financing activities</b>	<b>9,236,522</b>	<b>65,161,148</b>
<b>Net (decrease)/increase in cash and cash equivalents</b>	<b>(2,873,449)</b>	<b>32,519,729</b>
Cash and cash equivalents at the beginning of the period	26,979,105	27,091
Effects of exchange rate changes on cash and cash equivalents	140,283	42,877
<b>Cash and cash equivalents at end of the period</b>	<b>24,245,939</b>	<b>32,589,697</b>

*The above Consolidated statement of cash flows should be read in conjunction with the accompanying notes.*

## 1 Segment information

Management has determined, based on the reports reviewed by the chief operating decision maker that are used to make strategic decisions, that the group has one reportable segment being the research, development and commercialisation of health technologies. The segment details are therefore fully reflected in the body of the financial report.

## 2 Other income and expense items

### (a) Other income

	<b>Consolidated entity</b>	
	<b>31 December 2022</b>	31 December 2021
	\$	\$
Research and Development tax incentive (i)	<b>3,915,973</b>	-
Other items	<b>53,526</b>	24
	<b>3,969,499</b>	24

#### (i) Fair value of R&D tax incentive

At 31 December 2022, the group has accrued \$3,915,973 (2021: nil) in relation to the research and development spend for the current period.

## 3 Financial assets and financial liabilities

### (a) Trade and other receivables

	<b>31 December 2022</b>		<b>30 June 2022</b>		
	<b>Current</b>	<b>Non-current</b>	<b>Total</b>	<b>Current</b>	<b>Non-current</b>
	\$	\$	\$	\$	\$
Trade receivables	<b>162,254</b>	-	<b>162,254</b>	56,409	-
Accrued receivables (i)	<b>3,915,973</b>	-	<b>3,915,973</b>	-	-
Other receivables	<b>306</b>	-	<b>306</b>	73	-
	<b>4,078,533</b>	-	<b>4,078,533</b>	56,482	-

#### (i) Accrued receivables

Accrued receivables comprise \$3,915,973 from the Australian Taxation Office in relation to the R&D tax incentive (30 June 2022: nil).



### 3 Financial assets and financial liabilities (continued)

#### (b) Trade and other payables

	Notes	31 December 2022			30 June 2022		
		Current \$	Non- current \$	Total \$	Current \$	Non- current \$	Total \$
Trade payables		935,505	-	935,505	1,189,640	-	1,189,640
Amounts due to employees	12(a)	201,481	144,792	346,273	185,244	152,447	337,691
Accrued expenses		765,867	-	765,867	746,269	-	746,269
Other payables		15,454	-	15,454	32,165	-	32,165
		<b>1,918,307</b>	<b>144,792</b>	<b>2,063,099</b>	<b>2,153,318</b>	<b>152,447</b>	<b>2,305,765</b>

#### (c) Other financial liabilities

	31 December 2022			30 June 2022		
	Current \$	Non- current \$	Total \$	Current \$	Non- current \$	Total \$
Diaprost contingent consideration	5,166,052	2,922,559	8,088,611	-	7,592,929	7,592,929
NanoMab contingent consideration	5,682,657	-	5,682,657	5,588,620	-	5,588,620
NeoIndicate contingent consideration	113,815	228,705	342,520	-	144,207	144,207
NeoIndicate deferred consideration	44,280	-	44,280	43,548	-	43,548
Pivalate contingent consideration	784,000	-	784,000	-	-	-
TRIMT contingent consideration	-	4,763,653	4,763,653	-	4,650,362	4,650,362
	<b>11,790,804</b>	<b>7,914,917</b>	<b>19,705,721</b>	<b>5,632,168</b>	<b>12,387,498</b>	<b>18,019,666</b>

### 3 Financial assets and financial liabilities (continued)

#### (d) Recognised fair value measurements

##### (i) Fair value hierarchy

The following table provides the fair values of the group's financial instruments measured and recognised on a recurring basis after initial recognition and their categorisation within the fair value hierarchy. To provide an indication about the reliability of the inputs used in determining fair value, the group has classified its financial instruments into the three levels prescribed under the accounting standards. An explanation of each level follows underneath the table.

<b><i>Recurring fair value measurements</i></b>	<b>Level 1</b>	<b>Level 2</b>	<b>Level 3</b>	<b>Total</b>
<b>Consolidated entity - At 31 December 2022</b>	<b>\$</b>	<b>\$</b>	<b>\$</b>	<b>\$</b>
<b>Financial liabilities</b>				
NanoMab contingent consideration	-	-	5,682,657	5,682,657
Diaprost contingent consideration	-	-	8,088,611	8,088,611
TRIMT contingent consideration	-	-	4,763,653	4,763,653
Pivalate contingent consideration	-	-	784,000	784,000
NeolIndicate contingent consideration	-	-	228,706	228,706
<b>Total financial liabilities</b>	<b>-</b>	<b>-</b>	<b>19,547,627</b>	<b>19,547,627</b>

The group's policy is to recognise transfers into and transfers out of fair value hierarchy levels as at the end of the reporting period.

**Level 1:** The fair value of financial instruments traded in active markets (such as publicly traded derivatives and equity securities) is based on quoted market prices at the end of the reporting period. The quoted market price used for financial assets held by the group is the current bid price. These instruments are included in level 1.

**Level 2:** The fair value of financial instruments that are not traded in an active market (for example, over-the-counter derivatives) is determined using valuation techniques which maximise the use of observable market data and rely as little as possible on entity-specific estimates. If all significant inputs required to fair value an instrument are observable, the instrument is included in level 2.

**Level 3:** If one or more of the significant inputs is not based on observable market data, the instrument is included in level 3. This is the case for unlisted equity securities.

##### *Contingent consideration*

The fair value of contingent consideration relating to the acquisition of licences is estimated using a present value technique which discounts the management's estimate of the probability that the milestone will be achieved. For more information refer to note 4(a).

The discount rate used was 4.52%. The discount rate is based on benchmark interest rates provided by the Australian Taxation Office for the income year that agreements are entered into.

## 4 Non-financial assets and liabilities

### (a) Intangible assets

	AVb6 Integrin \$	hu PSA Anti-body \$	MAB \$	NanoMab \$	Other Intellectual Property \$	Total \$
<b>Half-year ended 31 December 2022</b>						
Opening net book amount	16,837,776	15,319,398	-	23,166,213	751,921	56,075,308
Additions	-	-	1,328,413	688,193	-	2,016,606
Amortisation charge	(446,419)	(551,187)	-	(646,747)	(449)	(1,644,802)
<b>Closing net book amount</b>	<b>16,391,357</b>	<b>14,768,211</b>	<b>1,328,413</b>	<b>23,207,659</b>	<b>751,472</b>	<b>56,447,112</b>
<b>At 31 December 2022</b>						
Cost	17,691,796	16,212,081	1,328,413	25,042,759	797,178	61,072,227
Accumulated amortisation and impairment	(1,300,439)	(1,443,870)	-	(1,835,100)	(45,706)	(4,625,115)
<b>Net book amount</b>	<b>16,391,357</b>	<b>14,768,211</b>	<b>1,328,413</b>	<b>23,207,659</b>	<b>751,472</b>	<b>56,447,112</b>

The group's intellectual property is measured at initial cost, less any accumulated amortisation and impairment losses.

#### (i) AVb6 Integrin

The group has recognised the Intellectual Property "AVb6 Integrin" through the acquisition of a license developed at TRIMT GmbH (TRIMT), a world-renowned independent research and treatment centre specialising in cancer, based in Radeberg, Germany.

It is the board's expectation that the acquired intellectual property will generate future economic benefits for the group. The amounts recognised as intangible assets relate to the upfront licenses fee paid in respect of the license agreement, value of equity issued to the licensor and contingent consideration. The contingent consideration arrangements require the group to pay the licensor at the completion of each milestone per the license agreements. The fair value of the contingent considerations was probability-adjusted based on the directors' assumptions, 70% probability of completing the first therapeutic milestone (milestone 3). Other milestones were deemed uncertain as per managements assessment.

AVb6 Integrin is amortised over a period of 20 years, being management's assessed useful life of the intangible asset.

#### (ii) hu PSA Anti-body

The group has recognised the Intellectual Property "hu PSA Anti-body" through the acquisition exclusive license developed at Diaprost AB (Diaprost), a world-renowned independent research and treatment centre specialising in prostate cancer, based in Lund, Sweden.

## **4 Non-financial assets and liabilities (continued)**

### **(a) Intangible assets (continued)**

#### *(ii) hu PSA Anti-body (continued)*

It is the board's expectation that the acquired intellectual property will generate future economic benefits for the group. The amounts recognised as intangible assets relate to the upfront licences fee paid in respect of the licence agreement and contingent consideration. The contingent consideration arrangements require the group to pay the licensor at the completion of each milestone per the licence agreements. The fair value of the contingent considerations was probability-adjusted based on the directors' assumptions, 70% probability of completing milestones 1 and 2.

hu PSA Anti-body is amortised over a period of 15 years, being management's assessed useful life of the intangible asset.

#### *(iii) NanoMab*

The board has recognised the Intellectual Property "NanoMab" through the acquisition of a licence developed at NanoMab Technology Limited, a world-renowned independent biopharmaceutical company focusing on cancer precision therapies through radiopharmaceuticals, based in Hong Kong.

It is the board's expectation that the acquired intellectual property will generate future economic benefits for the group. The amounts recognised as intangible assets relate to the upfront licenses fee paid in respect of the license agreement, value of equity issued to the licensor and contingent consideration. The contingent consideration arrangements require the group to pay the licensor at the completion of each milestone per the license agreements. The fair value of the contingent consideration on licence acquisition was probability-adjusted based on directors assumptions on completing milestone 1.

NanoMab is amortised over a period of 20 years, being management's assessed useful life of the intangible asset.

#### *(iv) MAb*

The group has recognised the Intellectual Property "MAb" through Radiopharm Ventures, LLC, a joint venture between Radiopharm Theranostics (USA), Inc and The Board of Regents of the University of Texas System and the MD Anderson Cancer Center.

It is the board's expectation that the acquired intellectual property will generate future economic benefits for the group. The amounts recognised as intangible assets relate to MD Anderson's investment in Radiopharm Ventures, LLC.

#### *(v) Other intellectual property*

Other intellectual property includes the following IP acquired by the group.

#### NeolIndicate

The group has recognised the Intellectual Property "NeolIndicate" through the acquisition of a sublicense developed at NeolIndicate LLC, a private research university based in Ohio.

It is the board's expectation that the acquired intellectual property will generate future economic benefits for the group. The amounts recognised as intangible assets relate to the upfront licences fee paid in respect of the licence agreement and contingent consideration. The contingent consideration arrangements require the group to pay the licensor at the completion of each milestone per the licence agreements.

NeolIndicate is amortised over a period of 16 years, being management's assessed useful life of the intangible asset.

## 4 Non-financial assets and liabilities (continued)

### (a) Intangible assets (continued)

#### (v) Other intellectual property (continued)

##### Pharma 15

The group has recognised the Intellectual Property "Pharma 15" through an agreement with Pharma 15 Corporation for the exclusive rights to purchase the Pharma 15 license from the corporation. It is the board's expectation that once the license is acquired, it will generate future economic benefits for the group. The amounts currently recognised are the upfront costs of signing the option agreement. The requirements of the agreement have been met and the negotiations are taking place at 31 December 2022. At the end of the reporting year management deemed the asset is not ready for use, thus no amortisation has been deducted from it.

##### Pivalate

The group has recognised the Intellectual Property "Pivalate" through the acquisition of a license developed at Cancer Research Technologies Limited (CRT), a world-renowned independent research and treatment centre for cancer, based in London, United Kingdom.

It is the board's expectation that the acquired intellectual property will generate future economic benefits for the group. The amounts recognised as intangible assets relate to the upfront licenses fee paid in respect of the license agreement and contingent consideration. The contingent consideration arrangements require the group to pay the licensor at the completion of each milestone per the license agreements. The group has reassessed the contingent consideration for Pivalate at 31 December 2022. deemed it not appropriate to include as the milestone targets were either concluded or ongoing, thus not payable by the group.

Pivalate is amortised over a period of 15 years, being management's assessed useful life of the intangible asset.

##### UCLA

The group has recognised the Intellectual Property "UCLA" through the acquisition of a license developed at The Regents of the University of California, a university based in California.

It is the board's expectation that the acquired intellectual property will generate future economic benefits for the group. The amounts recognised as intangible assets relate to the upfront licenses fee paid in respect of the license agreement and contingent consideration.

UCLA is amortised over a period of 19 years, being management's assessed useful life of the intangible asset.

#### (vi) Impairment test for intellectual property

The group's accounting policies and approach to assessing for indications of impairment in respect of intangible assets in use are followed consistently in the interim financial statements as compared with the most recent annual financial statements.

## 5 Equity

### (a) Share capital

	<b>31 December 2022 No.</b>	<b>31 December 2022 \$</b>	<b>30 June 2022 No.</b>	<b>30 June 2022 \$</b>
Ordinary Shares Fully paid	<b>328,534,705</b>	<b>95,698,275</b>	255,433,248	86,758,783

#### (i) Movements in ordinary shares

Details	Notes	Number of shares	Total \$
<b>Balance at 1 July 2022</b>		<b>255,433,248</b>	<b>86,758,783</b>
Issue at \$0.14 pursuant to institutional entitlement offer (2022-10-25)		39,878,805	5,583,033
Issue of forfeiture shares at \$0.171 (2022-10-26)		1,149,417	196,550
Issue at \$0.14 pursuant to rights issue (2022-11-25)		32,073,235	4,490,253
Less: Transaction costs arising on share issues		-	(1,330,344)
<b>Balance at 31 December 2022</b>		<b>328,534,705</b>	<b>95,698,275</b>

## 5 Equity (continued)

### (b) Other reserves

The following table shows a breakdown of the balance sheet line item 'other reserves' and the movements in these reserves during the period. A description of the nature and purpose of each reserve is provided below the table.

Notes	Share- based payments \$	Equity settled payments \$	Foreign currency translation \$	Total other reserves \$
<b>At 1 July 2022</b>	<b>6,554,312</b>	<b>573,865</b>	<b>(19,043)</b>	<b>7,109,134</b>
Currency translation differences	-	-	(911)	(911)
<b>Other comprehensive loss</b>	-	-	(911)	(911)
Transactions with owners in their capacity as owners				
Issue of shares as part of forfeiture payments	-	(196,550)	-	(196,550)
Provision of shares as part of forfeiture payments	-	203,095	-	203,095
Issue of options	2,350,786	-	-	2,350,786
Provision of equity settled payments	-	223,434	-	223,434
Forfeiture of options	(133,297)	-	-	(133,297)
<b>At 31 December 2022</b>	<b>8,771,801</b>	<b>803,844</b>	<b>(19,954)</b>	<b>9,555,691</b>

#### (i) Movements in options:

Details	Number of options	Total \$
<b>Opening balance 1 July 2022</b>	<b>41,553,372</b>	<b>6,554,312</b>
Issue of ESOP unlisted options	32,504,903	685,069
Issue of listed options	79,352,040	493,580
Forfeiture of ESOP unlisted options	(1,000,000)	(133,297)
Expense for share-based payments for options previously issued	-	1,172,137
<b>Balance at 31 December 2022</b>	<b>152,410,315</b>	<b>8,771,801</b>

## 6 Share-based payments

### (a) Employee Option Plan

#### (i) Fair value of options granted

The assessed fair value of options at grant date was determined using the Black-Scholes option pricing model that takes into account the exercise price, term of the option, security price at grant date and expected price volatility of the underlying security, the expected dividend yield, the risk-free interest rate for the term of the security and certain probability assumptions.

The model inputs for options granted under ESOP during the half-year ended 31 December 2022 included:

Grant date	Expiry date	Exercise price (\$)	No. of options	Share price at grant date (\$)	Expected volatility	Dividend yield	Risk-free interest rate	Fair value at grant date (\$)
2022-07-01	2027-07-01	0.170	13,137,976	0.170	100%	0.00%	3.24%	1,692,173
2022-11-16	2027-06-30	0.170	18,366,927	0.115	100%	0.00%	3.25%	1,529,964
2022-11-25	2026-11-30	0.200	7,400,000	0.110	100%	0.00%	3.27%	493,580
2022-11-28	2028-01-09	0.123	1,000,000	0.110	100%	0.00%	3.30%	82,800
			<b>39,904,903</b>					

The model inputs for options re-valued under ESOP during the half-year ended 31 December 2022 included:

Grant date	Expiry date	Exercise price (\$)	No. of options	Share price at grant date (\$)	Expected volatility	Dividend yield	Risk-free interest rate	Fair value at grant date (\$)
2022-11-16	2026-12-01	0.600	3,800,004	0.115	100%	0.00%	3.25%	194,940
			<b>3,800,004</b>					

## 7 Interests in other entities

### (a) Material subsidiaries

The group's principal subsidiaries at 31 December 2022 are set out below. Unless otherwise stated, they have share capital consisting solely of ordinary shares that are held directly by the group, and the proportion of ownership interests held equals the voting rights held by the group. The country of incorporation or registration is also their principal place of business.

Name of entity	Place of business/ country of incorporation	Ownership interest held by the group		Ownership interest held by non-controlling interests	
		31 December 2022	30 June 2022	31 December 2022	30 June 2022
		%	%	%	%
Radiopharm Theranostics (USA) Inc	United States	100	100	-	-
Radiopharm Ventures LLC	United States	51	-	49	-

On 9 July 2022, Radiopharm Theranostics (USA) Inc. and The University of Texas MD Anderson Cancer Center formed Radiopharm Ventures, LLC, a joint venture to develop novel radiopharmaceutical therapeutic products for cancer. The joint venture will focus initially on developing products based on MD Anderson intellectual property.



## 7 Interests in other entities (continued)

### (a) Material subsidiaries (continued)

Radiopharm Ventures, LLC is a limited liability company jointly owned by Radiopharm Theranostics (USA) Inc. (a wholly owned subsidiary of Radiopharm) (51%) and MD Anderson (49%). The University of Texas MD Anderson Cancer Center has granted a license to Radiopharm Ventures for certain patent and technology rights for development and commercialisation effective from 11 September 2022. The license may continue until the later of twenty years from the effective date or the end of the life of the licensed patents. The license may be terminated at any time by mutual written agreement. The agreement between Radiopharm Ventures and MD Anderson includes royalty and milestone payment obligations that arise from the development and/or commercialisation of licensed products. The costs will be shared by Radiopharm Theranostics (USA) Inc and MD Anderson and both parties will share ownership of the resultant intellectual property.

### (b) Non-controlling interests (NCI)

Set out below is summarised financial information for each subsidiary that has non-controlling interests that are material to the group. The amounts disclosed for each subsidiary are before inter-group eliminations.

	<b>Radiopharm Ventures, LLC</b>	
	<b>31 December</b>	31 December
	<b>2022</b>	2021
	\$	\$
<b>Summarised balance sheet</b>		
Current assets	1,531,167	-
Current liabilities	(147,601)	-
<b>Current net assets</b>	<b>1,383,566</b>	-
Non-current assets	1,328,413	-
<b>Non-current net assets</b>	<b>1,328,413</b>	-
<b>Net assets</b>	<b>2,711,979</b>	-
Accumulated NCI	1,255,632	-
	<b>Radiopharm Ventures, LLC</b>	
	<b>31 December</b>	31 December
	<b>2022</b>	2021
	\$	\$
<b>Summarised statement of comprehensive loss</b>		
Loss for the period	(148,532)	-
<b>Total comprehensive loss</b>	<b>(148,532)</b>	-
Loss allocated to NCI	(72,781)	-

## **8 Critical estimates, judgements and errors**

The preparation of financial statements requires the use of accounting estimates which, by definition, will seldom equal the actual results. Management also needs to exercise judgement in applying the group's accounting policies.

The group makes estimates and assumptions concerning the future. The resulting accounting estimates will, by definition, seldom equal the related actual results. The estimates and assumptions that have a significant risk of causing a material adjustment to the carrying amounts of assets and liabilities within the next financial period are discussed below.

### *Share-based payments*

The value attributed to share options issued is an estimate calculated using an appropriate mathematical formula based on an option pricing model. The choice of models and the resultant share option value require assumptions to be made in relation to the likelihood and timing of meeting the conditions of the shares and the value and volatility of the price of the shares.

### *Estimation of contingent consideration*

Contingent consideration includes amounts related to the provision of fees for the completion of milestones to licensors. For more information, please refer to Note 9.

## 9 Contingent liabilities

### (a) AVb6 Integrin intellectual property

The group has the licence agreement with TRIMT GmbH (TRIMT). The key financial terms of the licence agreement includes payments of cash and shares in the group worth US\$10 million.

The group may also incur liabilities contingent on future events in respect of the licence agreement, which are summarised below:

#### (i) Development milestone payments

Within 30 days after the occurrence of each milestone below, the group is required to pay TRIMT the amount indicated below:

Milestones	Requirements	Payment to TRIMT
1.	Commencement of Phase 3 diagnostic clinical trial for (68Ga-TRIVEHEXIN) (Diagnostic)	US\$2m
2.	Any Marketing Approval in Japan, China, Hong Kong or the United States of (68Ga-TRIVEHEXIN) for diagnostic application (Diagnostic)	US\$3m
3.	Last patient Phase 1 (Therapeutic)	US\$5m
4.	First patient Phase 2 (Therapeutic)	US\$10m
5.	Last patient Phase 2 (Therapeutic)	US\$10m
6.	First patient Phase 3 (Therapeutic)	US\$15m
7.	Last patient Phase 3 (Therapeutic)	US\$15m
8.	Any Marketing Approval in Japan, China, Hong Kong or the United States (Therapeutic)	US\$30m

Management expects milestone 3 to be met with 70% (30 June 2022: 70%) certainty, however it is uncertain whether other milestones will be met due to number of factors which are outside the group's control affect this outcome. Hence, management has accounted for those payments in relation to milestone 3 for this current reporting period.

#### (ii) Royalties on net sales

The group is obliged to pay TRIMT royalties on net sales based on industry standard single digit royalty rates and also on sublicense revenues.

## 9 Contingent liabilities (continued)

### (b) hu PSA Anti-body intellectual property

The group has the licence agreement with Diaprost AB. The key financial terms of the licence agreement include upfront cash payments of US\$7 million.

The group may also incur liabilities contingent on future events in respect of the licence agreement, which are summarised below:

#### (i) Development milestone payments

Within 30 days after the occurrence of each milestone below, the group is required to pay Diaprost the amount indicated below:

Milestones	Requirements	Payment to Diaprost
1.	IND allowance	US\$3m
2.	Last patient Phase 1	US\$5m
3.	First patient Phase 2	US\$11m
4.	Last patient Phase 2B	US\$11m
5.	First patient Pivotal Study	US\$15m
6.	Upon the dosing of the final patient in a Pivotal Study	US\$15m
7.	FDA submission	US\$7m
8.	FDA approval	US\$25m
9.	EMA approval	US\$10m
10.	PMDA approval	US\$5m
11.	Second indication, approval at first of FDA, EMA, PMDA	US\$10m
12.	Approval at first of FDA, EMA, PMDA for Diagnostic trials.	US\$5m

Management expects milestones 1 and 2 to be met with 70% (30 June 2022: 70%) certainty, however it is uncertain whether other milestones will be met due to number of factors which are outside the group's control affect this outcome. Hence, management has accounted for those payments in relation to the milestones 1 and 2 for this current reporting period.

#### (ii) Royalties

The group is obliged to pay Diaprost AB royalties on sublicensing based on industry standard royalty rates.

## 9 Contingent liabilities (continued)

### (c) NanoMab intellectual property

The group has the licence agreement with the NanoMab Technology Limited. The key financial terms of the licence agreement includes payments of cash and shares in the group worth US\$12.5 million.

The group may also incur liabilities contingent on future events in respect of the licence agreement, which are summarised below:

#### (i) Development milestone payments

Within 30 days after the occurrence of each milestone below, the group is required to pay Nanomab the amount indicated below:

Milestones	Requirements	Payment to Nanomab
1.	IND allowance by the U.S. FDA or the EMA or the NMPA (for either the HER-2 or the TROP-2 Therapeutic)	US\$5m*
2.	IND allowance by the U.S. FDA or the EMA or the NMPA (for the PKT-7 Therapeutic)	US\$0.5m*
3.	First patient dosed in the first Phase 1 therapeutic clinical trial	US\$1m*
4.	First patient dosed in the first Phase 2 therapeutic clinical trial	US\$2m*
5.	First patient dosed in the first Phase 3 therapeutic clinical trial, or approval of a Licensed Product	US\$3m*

\* Payment to be made in the form of ordinary shares in the group, based on the price of the 7 day volume weighted average price (VWAP) prior to the announcement of the milestone on the ASX.

Management expects milestone 1 and 2 to be met with 70% (30 June 2022: 70%) certainty, however it is uncertain whether other milestones will be met due to number of factors which are outside the group's control affect this outcome. Hence, management has accounted for those payments in relation to the milestone 1 and 2 for this current reporting period.

Additionally, the group signed an amendment with NanoMab Technology Limited that included the additional milestones. Within 30 days after occurrence of each milestone below, the group is required to pay NanoMab the amount indicated below:

Milestones	Requirements	Payment to Nanomab
1.	IND submission to the U.S. FDA or the EMA or the NMPA for PDL-1 Therapeutic)	US\$0.5m*
2.	First patient dosed in the first Phase 1 therapeutic clinical trial	US\$1m*
3.	First patient dosed in the first Phase 2 therapeutic clinical trial	US\$2m*
4.	First patient dosed in the first Phase 3 therapeutic clinical trial	US\$3m*

\* Payment to be made in the form of ordinary shares in the group, based on the price of the 7 day volume weighted average price (VWAP) prior to the announcement of the milestone on the ASX.

Management expects milestone 1 to be met with 70% (30 June 2022: 70%) certainty, however it is uncertain whether other milestones will be met due to number of factors which are outside the group's control affect this outcome. Hence, management has accounted for those payments in relation to the milestone 1 for this current reporting period.

## 9 Contingent liabilities (continued)

### (c) NanoMab intellectual property (continued)

#### (ii) *Royalties*

The group is obliged to pay Nanomab royalties on net sales based on industry standard single digit royalty rates and also on sublicense revenues.

### (d) Pivalate intellectual property

The group has the licence agreement with Cancer Research Technologies Limited (CRT). The key financial terms of the licence agreement include an upfront cash payment of £180,000.

The group may also incur liabilities contingent on future events in respect of the licence agreement, which are summarised below:

#### (i) *Development milestone payments*

Within 30 days after the occurrence of each milestone below, the group is required to pay Imperial the amount indicated below:

Diagnostic development milestones:

<b>Milestones</b>	<b>Requirements</b>	<b>Payment to Imperial</b>
1.	Phase 1 clinical trial commencement limited to each of the 1st indication	£45k
2.	Phase 2 clinical trial commencement limited to each of the 1st 3 indications	£225k
3.	Phase 3 clinical trial commencement limited to each of the 1st 3 indications	£630k
4.	Grant of US Regulatory Approval	£900k
5.	Grant of EU (or UK) Regulatory Approval	£450k
6.	First commercial sale	£900k
7.	Aggregate Net Sales worldwide exceeding £10m	£630k
8.	Aggregate Net Sales worldwide exceeding £50m	£3.15m

## 9 Contingent liabilities (continued)

### (d) Pivalate intellectual property (continued)

#### (i) Development milestone payments (continued)

Therapeutic development milestones:

Milestones	Requirements	Payment to Imperial
1.	Clearing of IND in the US or any country in Territory	£90k
2.	Phase 1 clinical trial/pivotal study commencement, limited to each of the 1st indication	£225k
3.	Phase 2 clinical trial/pivotal study commencement, limited to each of the 1st 3 indications	£630k
4.	Phase 3 clinical trial/pivotal study commencement, limited to each of the 1st 3 indications	£1.8m
5.	Grant of US Regulatory Approval	£3.6m
6.	Grant of MA in the EU (or UK)	£1.8m
7.	First commercial sale	£4.5m
8.	Aggregate Net Sales worldwide exceeding £100m	£2.7m
9.	Aggregate Net Sales worldwide exceeding £500m	£13.5m

Management expects Diagnostic milestone 3 to be met with 70% (30 June 2022: nil) certainty, however it is uncertain whether other milestones will be met due to number of factors which are outside the group's control affect this outcome. Hence, management has accounted for those payments in relation to the Diagnostic milestone 3 for this current reporting period.

#### (ii) Royalties

The group is obliged to pay CRT royalties on net sales based on industry standard single digit royalty rates.

## 9 Contingent liabilities (continued)

### (e) NeoIndicate intellectual property

The group has the sublicense agreement with NeoIndicate LLC (NeoIndicate). The key financial terms of the license agreement include an upfront cash payment of US\$100,000.

The group may also incur liabilities contingent on future events in respect of the licence agreement, which are summarised below:

#### (i) Development milestone payments

Within 30 days after the occurrence of each milestone below, the group is required to pay NeoIndicate the amount indicated below:

Diagnostic development milestones:

Milestones	Requirements	Payment to NeoIndicate
1.	eIND or IND Diagnostic approval	US\$75k
2.	First dose of Diagnostic in Phase I anywhere in world	US\$75k
3.	First dose of Diagnostic in Phase II anywhere in world	US\$150k
4.	First dose of Diagnostic in Phase III anywhere in world	US\$300k
5.	US FDA Regulatory Approval Diagnostic	US\$1m
6.	Outside of US Regulatory Approval Diagnostic	US\$0.5m
7.	Upon first reaching cumulative aggregate gross sales of \$25M Diagnostic	US\$0.75m
8.	Upon first reaching cumulative aggregate gross sales of \$100M Diagnostic	US\$3m
9.	Upon first reaching cumulative aggregate gross sales of US\$250M Diagnostic	US\$7.5m
10.	Upon first reaching cumulative aggregate gross sales of US\$500M Diagnostic	US\$15m
11.	Upon first reaching cumulative aggregate gross sales of US\$1 Billion Diagnostic	US\$30m
12.	Upon first reaching cumulative aggregate gross sales of US\$2 Billion Diagnostic	US\$60m



## 9 Contingent liabilities (continued)

### (e) NeoIndicate intellectual property (continued)

#### (i) Development milestone payments (continued)

Therapeutic Licenced Product Milestone Payments:

Milestones	Requirements	Payment to NeoIndicate
1.	eIND or IND approval of therapeutic	US\$100k
2.	First dosing Therapeutic of patients in Phase I anywhere in world	US\$100k
3.	First dosing Therapeutic of patients in Phase II anywhere in world	US\$200k
4.	First dosing Therapeutic of patients in Phase III anywhere in world	US\$0.5m
5.	US FDA Approval Therapeutic	US\$2m
6.	Outside of US Regulatory Approval Therapeutic	US\$1m
7.	Upon first reaching cumulative aggregate gross sales of \$25M Therapeutic	US\$1m
8.	Upon first reaching cumulative aggregate gross sales of \$100M Therapeutic	US\$5m
9.	Upon first reaching cumulative aggregate gross sales of \$250M Therapeutic	US\$10m
10.	Upon first reaching cumulative aggregate gross sales of US\$500M Therapeutic	US\$20m
11.	Upon first reaching cumulative aggregate gross sales of US\$1 Billion Therapeutic	US\$5m
12.	Upon first reaching cumulative aggregate gross sales of US\$2 Billion Therapeutic	US\$10m

Management expects Diagnostic milestones 1 and 2 to be met with 70% (30 June 2022: 70%), as well as Therapeutic milestones 1 to be met with 60% (30 June 2022: nil) certainty and milestone 2 80% (30 June 2022: nil) certainty. However it is uncertain whether other milestones will be met due to number of factors which are outside the group's control affect this outcome. Hence, management has accounted for those payments in relation to the Diagnostic and therapeutic milestones 1 and 2 for this current reporting year.

#### (ii) Royalties

The group is obliged to pay NeoIndicate royalties on net sales based on industry standard single digit royalty rates.

## 9 Contingent liabilities (continued)

### (f) UCLA intellectual property

The group has the licence agreement with The Regents of the University of California (UCLA). The key financial terms of the licence agreement include an upfront cash payment of US\$100,000

The group may also incur liabilities contingent on future events in respect of the licence agreement, which are summarised below:

#### (i) Development milestone payments

Within 30 days after the occurrence of each milestone below, the group is required to pay Imperial the amount indicated below:

Milestones	Requirements	Payment to UCLA
1.	Upon enrolling the first patient in a phase II clinical trial of a Licenced Product being developed in the Therapeutics Field	US\$100k
2.	Upon enrolling the first patient in a phase III clinical trial of a Licenced Product being developed in the Therapeutics Field	US\$250k
3.	Upon receiving FDA approval for a Licenced Product being developed in the Therapeutics Field	US\$2.5m
4.	Upon receiving EMA approval for a Licenced Product being developed in the Therapeutics Field	US\$2m
5.	Upon achieving a First Commercial Sale of a Licenced Product in the Therapeutics Field	US\$1m
6.	When cumulative Net Sales of all Licenced Products reaches fifty million dollars (\$50,000,000)	US\$1.5m
7.	Cumulative Net Sales of all Licenced Products reaches two hundred and fifty million dollars (\$250,000,000)	US\$5m

Management is uncertain whether milestones will be met due to number of factors which are outside the group's control affect this outcome. Hence, management has not accounted for any milestones for this current reporting year.

#### (ii) Royalties

The group is obliged to pay UCLA royalties on net sales based on industry standard single digit royalty rates.

## 9 Contingent liabilities (continued)

### (g) Radiopharm Ventures LLC

Radiopharm Ventures, LLC has entered into a service agreement in order to complete research and development activities associated with the Mab license. The company may incur liabilities contingent on future events in respect of the of the service agreement, which are summarised below:

Within 30 days after the occurrence of each event, the company is required to pay the amount indicated below:

Event	Requirements	Payment
1.	Submission of the Final Study Report as a result of the performance of the services under the agreement.	US\$100k
2.	Upon IND approval of single domain antibody (sdAb) target 1	US\$200k
3.	Upon IND approval of single domain antibody (sdAb) target 2	US\$200k

Balances for events 2 and 3 will not be payable if the company fails to obtain IND approval of any sdAb target generated pursuant to the service agreement within 5 years from signing of the agreement.

Management is uncertain whether these events will be met due to number of factors which are outside the group's control affect this outcome. Hence, management has not accounted for the events for this current reporting year.

## 10 Commitments

### (a) Research and development commitments

#### (i) *Pivalate intellectual property*

Under the License Agreement, a non-refundable annual license fee is payable to CRT of £9,000. This is payable within 30 days of the first, second, third and forth anniversaries of the effective date. Within 30 days of the fifth and each subsequent anniversary of the effective date and until the calendar year in which the first commercial sale of a licensed product occurs, Radiopharm shall pay to the CRT £18,000.

## 11 Events occurring after the reporting period

On 14 February 2023, Radiopharm Theranostics Limited announced the initiation of the process to obtain a secondary listing on the Nasdaq Capital Market. The group has filed a registration statement on Form 20-F with the US Securities and Exchange Commission (SEC) and a listing application with Nasdaq.

No other matter or circumstance has occurred subsequent to period end that has significantly affected, or may significantly affect, the operations of the group, the results of those operations or the state of affairs of the group or economic entity in subsequent financial periods.

## 12 Related party transactions

### (a) Transactions with key management personnel

The following transactions occurred with related parties:

	<b>31 December 2022</b>	30 June 2022
	\$	\$
<i>Other transactions</i>		
Forfeiture payments expense to key management personnel	<b>408,333</b>	337,691

#### (i) Forfeiture payments payable to key management personnel

The group has entered agreements to pay employees for forfeiture of long-term incentives with their former employment. At 31 December 2022 the group has recognised \$346,273 as payable for the current period. The expense is cumulative and vests dependent to the employees agreements with Radiopharm.

## 13 Loss per share

### (a) Reconciliation of earnings used in calculating loss per share

	<b>31 December 2022</b>	31 December 2021
	\$	\$
<i>Basic and diluted loss per share</i>		
Loss attributable to the ordinary equity holders of the group used in calculating basic/diluted loss per share:		
From continuing operations	<u>(12,552,283)</u>	<u>(17,390,804)</u>

### (b) Weighted average number of shares used as denominator

	<b>31 December 2022</b>	31 December 2021
	Number	Number
Weighted average number of ordinary shares used as the denominator in calculating basic and diluted loss per share	<u><b>276,641,824</b></u>	<u>108,689,880</u>

## **14 Basis of preparation of half-year report**

This interim financial report for the half-year period ended 31 December 2022 have been prepared in accordance with Accounting Standard AASB 134 *Interim Financial Reporting* and the *Corporations Act 2001*.

This interim report does not include all the notes of the type normally included in an annual financial report. Accordingly, this report is to be read in conjunction with the annual report for the year ended 30 June 2022 and any public announcements made by Radiopharm Theranostics Limited during the interim reporting period in accordance with the continuous disclosure requirements of the *Corporations Act 2001*.

### **(i) Going concern**

The financial statements have been prepared on the going concern basis, which contemplates continuity of normal business activities and the realisation of assets and settlement of liabilities in the normal course of business.

For the period ended 31 December 2022, the group incurred a net loss of \$12,552,283 and had cash outflows from operating activities of \$12,036,665 as at 31 December 2022. The ability of the group to continue as a going concern is principally dependent upon the ability of the group to raise sufficient capital and manage operating cashflow.

The directors believe that the group can raise capital as required based on the success of previous capital raises and the continued development of the group's projects.

In addition, the group can employ cash management strategies such as delaying or reducing some operating activities.

Based on the above, the directors are satisfied that the group has access to sufficient sources of funding to meet its commitments over the next 12 months, and for that reason the financial statements have been prepared on the basis that the group is a going concern.

Should the above assumptions not prove to be appropriate, there is material uncertainty whether the consolidated entity will continue as a going concern and therefore whether it will realise its assets and extinguish its liabilities in the normal course of business and at the amounts stated in these financial statements.

## **15 Summary of significant accounting policies**

This note provides a list of the significant accounting policies adopted in the preparation of these consolidated financial statements to the extent they have not already been disclosed in the other notes above. These policies have been consistently applied to all the periods presented, unless otherwise stated. The financial statements are for the group consisting of Radiopharm Theranostics Limited and its subsidiaries.

### **(a) Licensing revenues, including milestone revenue**

For licence revenue, and in order to determine whether to recognise revenue, the group follows a 5-step process:

- 1) Identifying the contract with a customer;
- 2) Identifying the performance obligations;
- 3) Determining the transaction price;
- 4) Allocating the transaction price to the performance obligations;
- 5) Recognising revenue when / as performance obligation(s) are satisfied.

Revenue from licences of the group's intellectual property reflects the transfer of a right to use the intellectual property as it exists at the point in time in which the licence is transferred to the customer.

## **15 Summary of significant accounting policies (continued)**

### **(a) Licensing revenues, including milestone revenue (continued)**

Licensing agreements are examined to determine whether they contain additional performance obligations, over and above the right to use the intellectual property. To the extent that additional performance obligations exist, the transaction price the consolidated entity expects to receive for the contract is allocated to the separate performance obligations.

The receipt of milestone payments is often contingent on meeting certain clinical, regulatory or commercial targets, and is therefore considered variable consideration. The transaction price of the contingent milestone is estimated using the most likely amount method. Within the transaction price, the price associated with the contingent milestone is included only to the extent that it is highly probable that a significant revenue reversal in the amount of cumulative revenue recognised will not occur. Milestone payments that are not within the control of the group, such as regulatory approvals, are not considered highly probable of being achieved until those approvals are achieved.

### **(b) Principal versus agent determination**

The group is required to determine whether it is acting as principal or agent with respect to various elements of agreements entered into as part of research and development collaborations. Whilst these collaborative arrangements may not fall directly within the scope of AASB 15: revenue from contracts with customers, the group considers the guidance in AASB 15 in order to determine whether it is the primary obligor and acting as principal for each element of the arrangement, or alternatively whether it is acting as Agent. If the group determines it is acting as principal revenue and expenses are presented gross within income statement. If the group is determined to be acting as an agent then the group recognises only the net amount to which it expects to be entitled when the respective performance obligation is satisfied.

In the directors' opinion:

- (a) the financial statements and notes set out on pages 1 to 35 are in accordance with the *Corporations Act 2001*, including:
  - (i) complying with AASB 134 *Interim Financial Reporting*, the *Corporations Regulations 2001* and other mandatory professional reporting requirements, and
  - (ii) giving a true and fair view of the consolidated entity's financial position as at 31 December 2022 and of its performance for the half-year ended ended on that date, and
- (b) there are reasonable grounds to believe that the group will be able to pay its debts as and when they become due and payable.

This declaration is made in accordance with a resolution of directors.



Mr Paul Hopper  
Executive Chairman

Sydney  
28 February 2023

## Independent Auditor's Review Report

### To the Members of Radiopharm Theranostics Limited

#### Report on the review of the half-year financial report

##### Conclusion

We have reviewed the accompanying half-year financial report of Radiopharm Theranostics Limited (the Company) and its subsidiaries (the Group), which comprises the consolidated statement of financial position as at 31 December 2022, and the consolidated statement of profit or loss and other comprehensive income, consolidated statement of changes in equity and consolidated statement of cash flows for the half year ended on that date, a description of accounting policies, other selected explanatory notes, and the directors' declaration.

Based on our review, which is not an audit, we have not become aware of any matter that makes us believe that the accompanying half-year financial report of Radiopharm Theranostics Limited does not comply with the *Corporations Act 2001* including:

- a giving a true and fair view of the Group's financial position as at 31 December 2022 and of its performance for the half-year ended on that date; and
- b complying with Accounting Standard AASB 134 *Interim Financial Reporting and the Corporations Regulations 2001*.

##### Basis for Conclusion

We conducted our review in accordance with ASRE 2410 *Review of a Financial Report Performed by the Independent Auditor of the Entity*. Our responsibilities are further described in the Auditor's Responsibilities for the Review of the Financial Report section of our report. We are independent of the Group in accordance with the auditor independence requirements of the *Corporations Act 2001* and the ethical requirements of the Accounting Professional and Ethical Standards Board's APES 110 *Code of Ethics for Professional Accountants (including Independence Standards)* (the Code) that are relevant to our audit of the annual financial report in Australia. We have also fulfilled our other ethical responsibilities in accordance with the Code.



### Material uncertainty related to going concern

We draw attention to Note 14(i) in the financial report, which indicates that the Group incurred a net loss of \$12,552,283 and had cash outflows from operating activities of \$12,036,665 for the half-year ended 31 December 2022. As stated in Note 14(i), these events or conditions, along with other matters as set forth in Note 14(i), indicate that a material uncertainty exists that may cast significant doubt on the Group's ability to continue as a going concern. Our conclusion is not modified in respect of this matter.

### Directors' responsibility for the half-year financial report

The Directors of the Group are responsible for the preparation of the half-year financial report that gives a true and fair view in accordance with Australian Accounting Standards and the *Corporations Act 2001* and for such internal control as the Directors determine is necessary to enable the preparation of the half-year financial report that gives a true and fair view and is free from material misstatement, whether due to fraud or error.

### Auditor's responsibility

Our responsibility is to express a conclusion on the half-year financial report based on our review. We conducted our review in accordance with Auditing Standard on Review Engagements ASRE 2410 *Review of a Financial Report Performed by the Independent Auditor of the Entity*, in order to state whether, on the basis of the procedures described, we have become aware of any matter that makes us believe that the half-year financial report is not in accordance with the *Corporations Act 2001* including giving a true and fair view of the Group's financial position as at 31 December 2022 and its performance for the half-year ended on that date, and complying with Accounting Standard AASB 134 *Interim Financial Reporting and the Corporations Regulations 2001*.

A review of a half-year financial report consists of making enquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Australian Auditing Standards and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

Grant Thornton Audit Pty Ltd  
Chartered Accountants

M A Cunningham  
Partner – Audit & Assurance

Melbourne, 28 February 2023



For personal use only

**Interim Report:**  
**Half-year ended**  
**31 December 2022**

**ASX:RAD**

